Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies

This report summarizes key issues contributing to the cost of preparing human pluripotent stem cell lines for use in cell therapy manufacturing based on discussion between stem cell banking experts from ten countries at a workshop session on 'cost of goods' for human pluripotent stem cell banking organized by the International Stem Cell Banking Initiative (ISCBI) held at the Korea National Institutes of Health in Korea (25(th) September 2019). In this report, we also build on the workshop discussion and highlight and discuss the full range of costs and unexpected challenges on resources for the delivery of stocks of hPSCs suitable for use as starting materials in the manufacture of stem cell-based medicines. The experiences of global leaders from different national resource centers highlight issues to consider in cost management and the possibilities for reducing costs while moving into the clinical application stage.

Automated summary

This report summarizes key issues discussed at a workshop organized by the International Stem Cell Banking Initiative (ISCBI) in Korea, highlighting the full range of costs and challenges related to preparing human pluripotent stem cell lines for cell therapy manufacturing. Global experts shared experiences on cost management and opportunities for reducing costs during the clinical application stage.